Bausch + Lomb’s SWOT analysis: ophthalmology leader faces spin-off uncertainty

Bausch + Lomb (BLCO) reported strong Q4 2024 results, exceeding expectations with 11% constant currency sales growth, and maintained a robust gross profit margin in Q2 2025, despite a lack of recent profitability. While analysts anticipate positive earnings for FY2025, the company's tempered 5.5-7.5% constant currency growth outlook for 2025, coupled with ongoing uncertainty surrounding a potential spin-off and foreign exchange headwinds, presents a mixed picture for investors. However, BLCO's strong ophthalmology product portfolio, particularly in Dry Eye Disease, and management's successful mitigation of tariff impacts, position it for continued growth within a positively viewed healthcare sector.

Analysis

Bausch + Lomb (BLCO) presents a mixed financial profile, balancing strong operational execution against strategic uncertainties and a tempered outlook. The company demonstrated underlying strength with an 11% constant currency sales growth in Q4 2024 and a robust 59.68% gross profit margin in Q2 2025, driven by its Vision Care, Contact Lens, and Surgical segments. Despite not being profitable over the last twelve months, analysts project a return to profitability in fiscal year 2025 with an estimated EPS of $0.50. However, this is offset by the company's own conservative 2025 guidance of 5.5-7.5% constant currency growth, which falls below consensus at the midpoint, and is further clouded by seven downward earnings revisions from analysts. A significant overhang for the stock is the continued uncertainty surrounding the timeline for a corporate spin-off, which contributes to analyst caution. Management has shown operational adeptness by successfully mitigating a 25-cent tariff headwind, but the growth thesis remains heavily dependent on new product launches and the market penetration of its key Dry Eye Disease drugs, Miebo and Xiidra, within a competitive ophthalmology market.

Key Decisions for Investors

• Investors should weigh BLCO's solid quarterly performance and strong product portfolio against the significant risks from its tempered growth guidance and the indefinite timeline of its corporate spin-off.
• Closely monitor the performance and market penetration of key growth drivers Miebo and Xiidra, as well as any management commentary that provides clarity on the spin-off, as these will be major catalysts for the stock.
• Given that the stock is viewed as slightly overvalued and faces headwinds from foreign exchange and corporate uncertainty, a cautious stance is warranted; consider awaiting a more favorable entry point or a resolution of the spin-off before building a significant position.